Tonix Pharmaceuticals Holding Corp. Share Price Today: Live Updates & Key Insights

Tonix Pharmaceuticals Holding Corp. share price today is $15.05, up -4.88%. The stock opened at $15.72 against the previous close of $15.77, with an intraday high of $16.75 and low of $15.

Tonix Pharmaceuticals Holding Corp. Share Price Chart

Tonix Pharmaceuticals Holding Corp.

us-stock
To Invest in {{usstockname}}
us-stock

Tonix Pharmaceuticals Holding Corp. Share Price Performance

$15.05 -0.0488(-4.88%) TNXP at 23 Mar 2026 03:32 PM Biotechnology
Lowest Today 15
Highest Today 16.75
Today’s Open 15.72
Prev. Close 15.77
52 Week High 69.97
52 Week Low 13.07
Day’s Range: Low 15 High 16.75
52-Week Range: Low 13.07 High 69.97
1 day return -
1 Week return +11.02
1 month return +5.78
3 month return -12.12
6 month return -43.98
1 year return -50.47
3 year return -87.98
5 year return -99.84
10 year return -

Tonix Pharmaceuticals Holding Corp. Institutional Holdings

BlackRock Inc 5.33

Vanguard Group Inc 5.27

Vanguard Total Stock Mkt Idx Inv 2.81

iShares Russell 2000 ETF 2.27

Geode Capital Management, LLC 2.13

Balyasny Asset Management LLC 1.45

Northern Trust Corp 1.33

State Street Corp 1.19

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Fidelity Small Cap Index 0.89

iShares Russell 2000 Value ETF 0.77

Nuveen, LLC 0.73

Davidson Kempner Capital Management LP 0.70

Northern Small Cap Value 0.63

NT Quality Small Cap Value 0.63

State St Russell Sm/Mid Cp® Indx SL Cl I 0.53

Nuveen Equity Index R6 0.53

Fidelity Extended Market Index 0.49

Vanguard Russell 2000 ETF 0.43

UBS Group AG 0.40

Vanguard US Momentum Factor ETF 0.34

State St Russell Sm Cap® Indx SL Cl I 0.29

Charles Schwab Investment Management Inc 0.26

Blackrock Extended Mkt Fund CF 0.26

iShares Micro-Cap ETF 0.24

Jane Street Group LLC 0.24

Susquehanna International Group, LLP 0.23

Schwab Small Cap Index 0.22

Extended Equity Market Fund K 0.22

NT R2000 Index Fund - NL 0.20

Millennium Management LLC 0.18

Fidelity Total Market Index 0.17

NT R2000 Index Fund - DC - NL - 3 0.16

XTX Topco Ltd 0.16

Bank of New York Mellon Corp 0.16

AQR Capital Management LLC 0.16

Man Group PLC 0.14

Morgan Stanley - Brokerage Accounts 0.12

Engineers Gate Manager LP 0.11

AllianceBernstein L.P. 0.10

Tonix Pharmaceuticals Holding Corp. Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Tonix Pharmaceuticals Holding Corp. Fundamentals

Market Cap 201.08 M

PB Ratio 0.8202

PE Ratio 0.0

Enterprise Value -5.25 M

Total Assets 277.17 M

Volume 1042945

Tonix Pharmaceuticals Holding Corp. Company Financials

Annual Revenue FY23:3989000 4.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:-112091000 -112.1M, FY21:-92312000 -92.3M, FY20:-50511000 -50.5M, FY19:-28828000 -28.8M

Annual Net worth FY23:-121016000 -121.0M, FY22:-115004000 -115.0M, FY21:-92212000 -92.2M, FY20:-50388000 -50.4M, FY19:-28382000 -28.4M

Quarterly Revenue Q3/2025:3290000 3.3M, Q2/2025:1998000 2.0M, Q1/2025:2429000 2.4M, Q3/2024:2822000 2.8M, Q2/2024:2208000 2.2M

Quarterly Profit Q3/2025:1923000 1.9M, Q2/2025:-1274000 -1.3M, Q1/2025:1486000 1.5M, Q3/2024:1267000 1.3M, Q2/2024:-1159000 -1.2M

Quarterly Net worth Q3/2025:-32009999 -32.0M, Q2/2025:-28272000 -28.3M, Q1/2025:-16829000 -16.8M, Q3/2024:-14213000 -14.2M, Q2/2024:-78776000 -78.8M

About Tonix Pharmaceuticals Holding Corp. & investment objective

Company Information Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Organisation Biotechnology

Employees 142

Industry Biotechnology

CEO Dr. Seth Lederman M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Tonix Pharmaceuticals Holding Corp. FAQs

What is the share price of Tonix Pharmaceuticals Holding Corp. today?

The current share price of Tonix Pharmaceuticals Holding Corp. is $15.05.

Can I buy Tonix Pharmaceuticals Holding Corp. shares in India?

Yes, Indian investors can buy Tonix Pharmaceuticals Holding Corp. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Tonix Pharmaceuticals Holding Corp. shares in India?

You can easily invest in Tonix Pharmaceuticals Holding Corp. shares from India by:

Can I buy fractional shares of Tonix Pharmaceuticals Holding Corp.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Tonix Pharmaceuticals Holding Corp.?

Tonix Pharmaceuticals Holding Corp. has a market cap of $201.08 M.

In which sector does Tonix Pharmaceuticals Holding Corp. belong?

Tonix Pharmaceuticals Holding Corp. operates in the Biotechnology sector.

What documents are required to invest in Tonix Pharmaceuticals Holding Corp. stocks?

To invest, you typically need:

What is the PE and PB ratio of Tonix Pharmaceuticals Holding Corp.?

The PE ratio of Tonix Pharmaceuticals Holding Corp. is N/A and the PB ratio is 0.82.